Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Mössner, Ekkehard; Brünker, Peter; Moser, Samuel; Püntener, Ursula; Schmidt, Carla; Herter, Sylvia; Grau, Roger; Gerdes, Christian; Nopora, Adam; van Puijenbroek, Erwin; Ferrara, Claudia; Sondermann, Peter; Jäger, Christiane; Strein, Pamela; Fertig, Georg; Friess, Thomas; Schüll, Christine; Bauer, Sabine; Dal Porto, Joseph; Del Nagro, Christopher; Dabbagh, Karim; J.S. Dyer, Martin; Poppema, Sibrand; Klein, Christian; Umaña, Pablo

doi:10.1182/blood-2009-06-225979

Public

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Published in Blood • Mar 1, 2010

Authors:

Ekkehard Mössner

Peter Brünker

Samuel Moser

Abstract

CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal antibodies against CD20, such as rituximab, has revolutionized the treatment of these disorders, greatly improving overall s...

Subject

CD20

Rituximab

Antibody-dependent cell-mediated cytotoxicity

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!